Novo Nordisk A/S (NVO)
39.05
-0.38
(-0.96%)
USD |
NYSE |
Oct 23, 16:00
39.01
-0.04
(-0.10%)
After-Hours: 20:00
Novo Nordisk Enterprise Value : 145.21B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 145.21B |
| October 22, 2026 | 146.48B |
| October 21, 2026 | 145.24B |
| October 20, 2026 | 146.21B |
| October 19, 2026 | 143.10B |
| October 16, 2026 | 144.47B |
| October 15, 2026 | 145.78B |
| October 14, 2026 | 142.10B |
| October 13, 2026 | 141.90B |
| October 12, 2026 | 143.64B |
| October 09, 2026 | 143.84B |
| October 08, 2026 | 142.30B |
| October 07, 2026 | 142.57B |
| October 06, 2026 | 140.12B |
| October 05, 2026 | 140.16B |
| October 02, 2026 | 139.42B |
| October 01, 2026 | 139.69B |
| September 30, 2026 | 141.39B |
| September 29, 2026 | 142.73B |
| September 28, 2026 | 144.07B |
| September 25, 2026 | 144.37B |
| September 24, 2026 | 143.77B |
| September 23, 2026 | 142.26B |
| September 22, 2026 | 146.38B |
| September 21, 2026 | 147.72B |
| Date | Value |
|---|---|
| September 18, 2026 | 159.23B |
| September 17, 2026 | 159.06B |
| September 16, 2026 | 154.11B |
| September 15, 2026 | 156.85B |
| September 14, 2026 | 159.93B |
| September 11, 2026 | 158.66B |
| September 10, 2026 | 161.80B |
| September 09, 2026 | 163.64B |
| September 08, 2026 | 165.65B |
| September 04, 2026 | 170.47B |
| September 03, 2026 | 173.52B |
| September 02, 2026 | 171.04B |
| September 01, 2026 | 165.52B |
| August 31, 2026 | 166.22B |
| August 28, 2026 | 167.16B |
| August 27, 2026 | 169.33B |
| August 26, 2026 | 172.44B |
| August 25, 2026 | 177.36B |
| August 24, 2026 | 171.54B |
| August 21, 2026 | 170.94B |
| August 20, 2026 | 168.93B |
| August 19, 2026 | 170.07B |
| August 18, 2026 | 167.49B |
| August 17, 2026 | 164.72B |
| August 14, 2026 | 168.09B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 558.20B |
| GSK Plc | 122.11B |
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.265B |
| Revenue (Quarterly) | 12.21B |
| Total Expenses (Quarterly) | 8.946B |
| EPS Diluted (Quarterly) | 0.7362 |
| Gross Profit Margin (Quarterly) | 78.21% |
| Profit Margin (Quarterly) | 26.74% |
| Earnings Yield | 10.48% |
| Operating Earnings Yield | 13.45% |
| Normalized Earnings Yield | 10.90 |